2F5 Stock Chart & Stats
€0.21
>-€0.01(-0.94%)
At close: 4:00 PM EDT
€0.21
>-€0.01(-0.94%)
Day’s Range― - ―
52-Week Range€0.20 - €2.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€917.46K
Enterprise Value€8.17
Total Cash (Recent Filing)€3.11M
Total Debt (Recent Filing)€3.50M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3837.20
Shares Outstanding3,959,792
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved CapitalizationThe balance sheet shows materially improved equity and manageable leverage versus 2022–2023, providing greater financial flexibility. This durable improvement reduces immediate insolvency risk, supports integration of strategic initiatives and gives management time to execute commercial or CDMO growth plans without immediate distress.
CDMO Platform ExpansionAcquiring Recipharm Israel expands manufacturing capacity and capabilities across biologics, sterile injectables and APIs, creating a more diversified CDMO revenue base. Structurally, this shifts part of the firm's model toward fee-for-service revenue, which can generate steadier cash flows and reduce dependence on single-program biotech risk over the medium term.
Early Commercialization TractionPositive TTM revenue growth from minimal historic sales indicates initial commercial progress and demand capture. If sustained, this trend supports scaling CDMO operations and product commercialization, improving the company's ability to convert R&D into recurring revenues and to reduce reliance on external financing over several quarters.
Bears Say
Persistent Cash BurnConsistent negative operating cash flow reflects sustained cash burn that will require continued external funding or significant operational cuts. Over a multi-quarter horizon, this constrains investment in pipeline programs and CDMO integration, increases refinancing risk and places pressure on management to materially grow revenue or reduce costs to achieve cash neutrality.
Negative Gross Profit And Large Operating LossesNegative gross profit and outsized operating losses versus modest revenue indicate the cost structure remains aligned to development-stage operations rather than scaled sales. This structural margin shortfall hinders path to sustainable profitability and means that even improving top-line will need substantial scale or cost reallocation to yield positive operating leverage.
Acquired Subsidiary Neargoing-concernThe acquired Recipharm Israel entity carried losses, a working capital deficit and an auditor going-concern note, creating integration and funding risk. Consolidating a loss-making CDMO raises near-term capital needs, may dilute cash benefits from the deal, and can increase execution risk as management must stabilize and fund the subsidiary while scaling commercial operations.
Scinai Immunotherapeutics News
2F5 FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was €0.20 and its highest was €2.28 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is €917.46K.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 20 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Jun 10, 2026. The company reported €0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 3,959,792 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of €0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.816%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in DE:2F5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
GT Biopharma
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―